Ask about this productRelated genes to: LCOR antibody
- Gene:
- LCOR NIH gene
- Name:
- ligand dependent nuclear receptor corepressor
- Previous symbol:
- C10orf12
- Synonyms:
- MLR2, FLJ38026, KIAA1795, DKFZP564P1916, FLJ13022
- Chromosome:
- 10q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2006-06-14
- Date modifiied:
- 2016-10-18
Related products to: LCOR antibody
Related articles to: LCOR antibody
- • CTS in HLHS can masquerade as an atrial septum. • T-cor and L-cor are a spectrum of CTS. • Prenatal assessment of LA morphology can assist with diagnosis of this high-risk entity. - Source: PubMed
Publication date: 2025/11/08
Rushing MarkPhilip RanjitJoshi VijayaKramer JenniferDooley AngelaSwaminathan Nithya - - Source: PubMed
Publication date: 2026/01/29
Mur PilarPozuelo AnnaTabernero JosepAlbanell JoanBellosillo BeatrizBosch FrancescBriones JavierBrunet JoanColomer DolorsDomènech MontserratFontanet Joan ManelMatias-Guiu XavierSalazar RamonVivanco-Hidalgo Rosa MariaMollà MeritxellMoreno LucasPrat AleixRibera Josep MariaClèries RamónGuarga AlexPiñol Josep A EspinàsBorras Josep Maria - In this paper, a new multiclass Alzheimer diagnosis system is proposed using Broad Learning (BL) and the combination of Local Coherence (LCOR) and Intrinsic Connectivity Contrast (ICC) parameters. A public resting state fMRI database; including healthy elderly subjects (HC), Alzheimer Disease (AD) and Mild Cognitive Impairment (MCI) patients; was chosen in this study. All rs-fMRI pre-processing and analysis were performed by CONN toolbox. Three contrast cases of AD, MCI and HC were implemented within the group-level analysis, then both LCOR and ICC parameters of the effected brain clusters were combined and collected. For diagnosis system, Broad Learning (BL) classifier is trained to classify three stages of AD, MCI and HC, respectively. Referring to the experimental results and compared with other current studies, the proposed system achieved high average accuracy of 99.6% with low training time of 2 s. Furthermore, a mapping between effected brain regions and their functions is given to interprets the common symptoms for AD and MCI patients. - Source: PubMed
Publication date: 2026/01/14
Issa SaliWang QiQi RuinanPeng GuangxiYin ShiPeng Qinmu - Estrogen receptor (ER) breast malignancies are poorly infiltrated by immune cells, hence exhibiting limited sensitivity to immune checkpoint inhibitors (ICIs). Recent data from Palomeque et al. demonstrate that ER signaling actively contributes to such an immunoevasive phenotype by preventing the nuclear factor LCOR from establishing an ICI-sensitive tumor microenvironment. - Source: PubMed
Publication date: 2025/12/17
Galassi ClaudiaGalluzzi Lorenzo - Hormone receptor-positive (HR+) breast cancers (BCs) are typically "immune-cold," poorly immune-infiltrated tumors that do not respond to immune-checkpoint blockade (ICB) therapies. Using clinical data, we report that estrogen receptor α (ERα) signaling was associated with immunosuppressive pathways and a lack of response to ICB in patients with HR+ BC. In this study, we validated ER-mediated immunosuppression by engineering and modulating the ER in preclinical models in vitro, in vivo, and ex vivo. Mechanistically, we found that ERα hijacked LCOR, a nuclear receptor corepressor, thereby preventing LCOR's function in the induction of tumor immunogenicity and immune infiltration, which is normally observed in the absence of ERα, such as in ER- BC. In HR+ BC, we demonstrate that the molecular disruption of LCOR and ERα interaction using anti-ER therapies or using a mutant of the LCOR nuclear receptor-binding domain (LSKLL into LSKAA) that does not interact with ERα, restored the immunogenic functions of LCOR. Remarkably, the LCOR-ERα disruption converted HR+ BC immune-cold tumors into immune-hot tumors responsive to ICB by increased antigen presentation machinery expression, immune infiltration, T cell recognition, and T cell-mediated killing. In conclusion, ERα inhibition and the disruption of LCOR-ERα interaction represent a therapeutic strategy and an opportunity to elicit immunotherapeutic benefit in patients with HR+ BC. - Source: PubMed
Publication date: 2025/11/25
Palomeque José ÁngelSerra-Mir GabrielBlasco-Benito SandraBrunel HelenaTorren-Duran PauPérez-Núñez IvánCannatá ChiaraComerma LauraMenendez SilviaServitja SoniaMartos TamaraCastro MariaBorges Rodrigo LLópez-Velazco Joanna IManzano SaraDuro-Sánchez SantiagoArribas JoaquínCaffarel María MUrruticoechea AnderSeoane José AMorey LluisAlbanell JoanCelià-Terrassa Toni